^
CANCER:

Pancreatic Ductal Adenocarcinoma

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
No biomarker
Pancreatic Ductal Adenocarcinoma
SBP-101
Sensitive
:
B
No biomarker
Pancreatic Ductal Adenocarcinoma
gemcitabine
Sensitive
:
B
No biomarker
Pancreatic Ductal Adenocarcinoma
gemcitabine + capecitabine
Sensitive
:
B
CCL11 overexpression
Pancreatic Ductal Adenocarcinoma
tertomotide
Sensitive
:
B
No biomarker
Pancreatic Ductal Adenocarcinoma
LSTA1
Sensitive
:
B
KRAS wild-type
Pancreatic Ductal Adenocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive
:
B
KRAS wild-type
Pancreatic Ductal Adenocarcinoma
5-fluorouracil + oxaliplatin
Sensitive
:
B
BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive
:
C1
ATM mutation
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive
:
C1
BRCA1 mutation
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive
:
C1
KRAS mutation
Pancreatic Ductal Adenocarcinoma
pembrolizumab + trametinib
Sensitive
:
C2
HGF-H
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Resistant
:
C3
MSI-L/dMMR
Pancreatic Ductal Adenocarcinoma
nivolumab
Sensitive
:
C3
MSI-L/dMMR
Pancreatic Ductal Adenocarcinoma
ipilimumab
Sensitive
:
C3
MSI-L/dMMR
Pancreatic Ductal Adenocarcinoma
pembrolizumab
Sensitive
:
C3
PALB2 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive
:
C3
BRCA1 mutation + BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive
:
C3
FANCF mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive
:
C3
MSH2 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive
:
C3
BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive
:
C3
BRCA1 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive
:
C3
DDR
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive
:
C3
C3M/PRO-C3 ratio elevation
Pancreatic Ductal Adenocarcinoma
PEGPH20
Sensitive
:
C3
PALB2 mutation
Pancreatic Ductal Adenocarcinoma
cisplatin + gemcitabine
Sensitive
:
C3
BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
cisplatin + gemcitabine
Sensitive
:
C3
BRCA1 mutation
Pancreatic Ductal Adenocarcinoma
cisplatin + gemcitabine
Sensitive
:
C3
GATA6 underexpression
Pancreatic Ductal Adenocarcinoma
leucovorin calcium
Resistant
:
C3
GATA6 underexpression
Pancreatic Ductal Adenocarcinoma
5-fluorouracil
Resistant
:
C3
GATA6 expression
Pancreatic Ductal Adenocarcinoma
gemcitabine
Resistant
:
C3
LAMC2 overexpression
Pancreatic Ductal Adenocarcinoma
gemcitabine
Resistant
:
C3
ATM mutation
Pancreatic Ductal Adenocarcinoma
durvalumab + gemcitabine + CP-675206
Sensitive
:
C3
ARID1A mutation
Pancreatic Ductal Adenocarcinoma
Immunotherapy
Sensitive
:
C3